Clinical Trials Logo

Filter by:
NCT ID: NCT03708211 Completed - Clinical trials for Neoplasms, Advanced Solid

A Study to Assess the Relative Bioavailability, Effect of Food, and Gastric Potential Hydrogen (pH) Modification on the Pharmacokinetics (PK) of TAK-931 in Participants With Advanced Solid Tumors

Start date: March 28, 2019
Phase: Phase 1
Study type: Interventional

The purpose of this study is to estimate the relative bioavailability of TAK-931 tablets in reference to powder-in capsule (PIC) and to assess the effect of food and esomeprazole on the pharmacokinetics (PK) of TAK-931 as a tablet.

NCT ID: NCT03707743 Recruiting - Aortic Dissection Clinical Trials

Registry of Patients With Acute/Subacute Type B Aortic Dissection Treated by Means of the STABILISE Technique (STABILISE)

STABILISE
Start date: October 30, 2018
Phase:
Study type: Observational [Patient Registry]

The aim of the study is to evaluate results of patients treated with the STABILISE technique for acute/subacute aortic dissection. Results and postoperative events are reported in accordance with the current reporting standards for endovascular aortic repair prepared and revised by the Ad Hoc Committee for Standardized Reporting Practices in Vascular Surgery of The Society for Vascular Surgery/American Association for Vascular Surgery

NCT ID: NCT03706365 Active, not recruiting - Prostate Cancer Clinical Trials

A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer

CYCLONE 2
Start date: November 26, 2018
Phase: Phase 2/Phase 3
Study type: Interventional

This study is being done to see how safe and effective abemaciclib is when given together with abiraterone acetate plus prednisone in participants with metastatic castration resistant prostate cancer. Prednisolone may be used instead of prednisone per local regulation.

NCT ID: NCT03705507 Terminated - Clinical trials for Acute Lymphoblastic Leukemia

International Trial of Selumetinib in Combination With Dexamethasone for the Treatment of Acute Lymphoblastic Leukaemia

SeluDex
Start date: May 18, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

This trial is to investigate the combination of selumetinib and dexamethasone in the treatment of acute lymphoblastic leukaemia (ALL) in both adults and children. Phase I is to find the most suitable dose of selumetinib to safely give with dexamethasone. Phase II will use this dose to find out how well the combination works.

NCT ID: NCT03705403 Active, not recruiting - NSCLC Stage IV Clinical Trials

IMMUNOtherapy and Stereotactic ABlative Radiotherapy (IMMUNOSABR) a Phase II Study

IMMUNOSABR2
Start date: April 4, 2019
Phase: Phase 2
Study type: Interventional

This will be a phase II trial testing if the combination of stereotactic ablative body radiotherapy (SABR) and L19-IL2 improve the progression-free survival in patients with limited metastatic non-small cell lung cancer (NSCLC). The trial consists of one cohort with two arms; C-arm and an E-arm. Patients with oligometastatic disease will receive SABR to minimal 1 and max all metastatic sites (max 5 sites irradiated) and patients with diffuse metastatic lesions (6 to max 10) will receive radiotherapy to max 5 sites. In the experimental arm, immunotherapy will be given after irradiation.

NCT ID: NCT03704415 Active, not recruiting - Asthma Clinical Trials

Aggravated Airway Inflammation: Research on Genomics and Optimal Operative Treatment (AirGOs Operative)

Start date: October 23, 2018
Phase: N/A
Study type: Interventional

This randomized study compares operative techniques in chronic rhinosinusitis with polyposis (CRSwNP) surgery. It aims to evaluate outcomes in asthma and CRSwNP, safety and costs. The investigators want to see if patients with certain clinical and/or genetic predispositions will benefit from extended surgery. They also aim to find biomarkers for detection and management models for of severe airway inflammation and to further develop markers for progressive disease forms.

NCT ID: NCT03703947 Recruiting - Clinical trials for Abdominal Aortic Aneurysm

Biomarker Profiling in Abdominal Aortic Aneurysm Patients

BIOMArCS-AAA
Start date: March 23, 2017
Phase:
Study type: Observational

The BIOMArCS-AAA study aims to investigate the associations of (temporal patterns of) blood biomarkers with aneurysm growth in patients with abdominal aortic aneurysm (AAA), with particular attention to biomarkers that have demonstrated prognostic value for adverse disease outcomes in coronary artery disease and biomarkers for the main genetic pathways associated with AAA.

NCT ID: NCT03703310 Completed - Clinical trials for Basal Cell Nevus Syndrome

Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas (BCCs) in Subjects With Basal Cell Nevus Syndrome (Gorlin Syndrome)

Start date: February 19, 2019
Phase: Phase 3
Study type: Interventional

This is a global, multicenter, randomized, double-blind, stratified, vehicle-controlled study of the efficacy and safety of Patidegib Topical Gel, 2%, applied topically twice daily to the face of adult participants with Gorlin syndrome. Participants will be required to apply the investigational product for 12 months. The primary endpoint is a comparison between the two treatment arms of the number of new BCCs that develop over the 12 month period.

NCT ID: NCT03703297 Active, not recruiting - Clinical trials for Small Cell Lung Cancer

Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy

ADRIATIC
Start date: September 27, 2018
Phase: Phase 3
Study type: Interventional

This is a Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center, International Study of Durvalumab or Durvalumab and Tremelimumab as Consolidation Treatment for Patients with LS-SCLC Who Have Not Progressed Following Concurrent Chemoradiation Therapy

NCT ID: NCT03703050 Recruiting - Clinical trials for Relapsing/Refractory ALK+ Anaplastic Large Cell Lymphoma

Nivolumab for Pediatric and Adult Relapsing/Refractory ALK+, for Evaluation of Response in Patients With Progressive Disease (Cohort 1) or as Consolidative Immunotherapy in Patients in Complete Remission After Relapse (Cohort 2)

NIVO-ALCL
Start date: January 2, 2019
Phase: Phase 2
Study type: Interventional

Prospective, non-randomized, single arm phase II trial with 2 cohorts of ALK+ ALCL treated with nivolumab